The Staying Power of Immunotherapies: Approaching Melanoma Care from an Inclusive Perspective

Melanoma can be a life-threatening condition if left untreated. Patients with skin of color often face delays in diagnosis and treatment initiation in melanoma care. These disparities point to the need for increased awareness and education on melanoma risk and identification for clinicians and patients. Immunotherapies as mono and combination therapeutic regimens have become the gold standard in melanoma management. As additional data on efficacy and safety of these agents continue to emerge, clinicians must be well equipped with evidence-based knowledge on strategies for prompt diagnosis, patient-centered education, and treatment selection to ensure the most optimal health outcomes.


Target Audience

This activity is designed for an audience of physicians, pharmacists, nurses and professional staff members of medical practices specializing in oncology, dermatology, and primary care.

Learning Objectives

  • Describe an evidence-based strategy to detect and diagnosis melanoma in SoC to initiate treatment early
  • Discuss clinical data for new and emerging treatments for melanoma
  • Identify evidence-based strategies in selecting treatment agents for melanoma that demonstrate improved efficacy and safety profiles
  • Summarize evidence-based strategies for managing adverse treatment-related effects in patients with melanoma potentially to improve patient QoL, adherence, and health outcomes
Course summary
Available credit: 
  • 1.75 ACPE Pharmacy
  • 1.75 AMA PRA Category 1 Credit
  • 1.75 ANCC
  • 1.75 Participation
Course opens: 
Course expires: 


  • This program addresses disparities in detection and diagnosis of melanoma in patients with skin of color along with expert guidance on patient education and treatment selection strategies with the inclusion of case-based learning

Program Agenda

  • Brief Introduction/pre-event test questions
  • Addressing health disparities in melanoma care: the importance of increased awareness
  • Discussing the clinical data of novel and emerging agents in melanoma
  • Evidence-based management of skin toxicities
    • The role of the dermatologist in managing toxicities
    • The role of the oncologist

Conclusion/ Faculty Q&A discussion (20 min)

  • Case studies based on daily clinical interactions in a real-world setting

Michael Atkins, MD

Deputy Director

Georgetown-Lombardi Comprehensive Cancer Center

Washington, DC


Laura Ferris, MD, PhD

Professor of Dermatology

University of Pittsburgh School of Med

Pittsburgh, PA


Disclosure of Conflicts of Interest

It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with ineligible companies whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are mitigated by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose.

Name of Faculty or Presenter

Reported Financial Relationship

Michael Atkins, MD

Advisory Boards: 

BMS, Merck, Novartis, Eisai, Aveo, Pfizer, Werewolf, Fathom, Pyxis Oncology, PACT, Elpis, X4Pharma, ValoHealth, ScholarRock, Surface, Takeda, Simcha, Roche, SAB Bio, Exelixis, Iovance, COTA, Idera, Agenus, Asher Bio, AstraZeneca, Calithera, SeaGen, Sanofi, OncoRena, GSK

Individual stocks and stock options: Werewolf, Pyxis Oncology

Contracted Research: BMS, Merck 

Laura Ferris, MD, PhD

Consulting:  DermTech, Castle Biosciences 

Independent Contractor:  DermTech, Castle Biosciences 

Accredited Provider Disclosures

Dorothy Caputo, MA, BSN, RN - CE Director of Accreditations has nothing to disclose.

Dorothy A. Duffy, RPh- AKH Pharmacy Reviewer has nothing to disclose.

Michele Bielarski, RN - Nurse Reviewer has nothing to disclose.

AKH Planners and Reviewers have nothing to disclose.


Planners’ and Managers’ Disclosures

LiVDerm Planners and Reviewers have nothing to disclose.

All of the relevant financial relationships listed for these individuals have been mitigated.


This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant's misunderstanding of the content.


Disclosure of Unlabeled Use and Investigational Product

This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

AKH Privacy Policy link:

Jointly provided by AKH Inc., Advancing Knowledge in Healthcare and Tarsus Cardio dba LivDerm

Estimated time to complete activity: 1 hour and 45 minutes

Commercial Support

This activity is supported by an educational grant from Merck Sharpe & Dohme Corp, a subsidiary of Merck & Co., Inc.

Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and Tarsus Cardio dba LiVDerm. AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

AKH Inc., Advancing Knowledge in Healthcare designates this enduring material activity for a maximum of 1.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

1.75 ANCC contact hour

Pharmacist Continuing Education

AKH Inc., Advancing Knowledge in Healthcare designates this continuing education activity for 1.75 contact hours.


Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser.






Available Credit

  • 1.75 ACPE Pharmacy
  • 1.75 AMA PRA Category 1 Credit
  • 1.75 ANCC
  • 1.75 Participation
Please login or register to take this course.

Required Hardware/software

A computer with an internet connection

Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser

Other additional software may be required such as PowerPoint or Adobe Acrobat Reader.